US 11,712,476 B2
Lipids and compositions for the delivery of therapeutics
Muthiah Mancharan, Cambridge, MA (US); Muthusamy Jayaraman, Cambridge, MA (US); Kallanthottathil G. Rajeev, Cambridge, MA (US); Laxman Eltepu, Cambridge, MA (US); Steven Ansell, Cambridge, MA (US); and Jianxin Chen, Cambridge, MA (US)
Assigned to ARBUTUS BIOPHARMA CORPORATION, Vancouver (CA)
Filed by ARBUTUS BIOPHARMA CORPORATION, Burnaby (CA)
Filed on Jun. 24, 2021, as Appl. No. 17/357,122.
Application 17/357,122 is a continuation of application No. 15/617,520, filed on Jun. 8, 2017, granted, now 11,077,197.
Application 15/617,520 is a continuation of application No. 14/884,489, filed on Oct. 15, 2015, granted, now 9,707,292, issued on Jul. 18, 2017.
Application 14/884,489 is a continuation of application No. 13/128,283, granted, now 9,186,325, issued on Nov. 17, 2015, previously published as PCT/US2009/063927, filed on Nov. 10, 2009.
Claims priority of provisional application 61/234,098, filed on Aug. 14, 2009.
Claims priority of provisional application 61/225,898, filed on Jul. 15, 2009.
Claims priority of provisional application 61/185,438, filed on Jun. 9, 2009.
Claims priority of provisional application 61/171,439, filed on Apr. 21, 2009.
Claims priority of provisional application 61/154,350, filed on Feb. 20, 2009.
Claims priority of provisional application 61/113,179, filed on Nov. 10, 2008.
Prior Publication US 2022/0023427 A1, Jan. 27, 2022
Int. Cl. A61K 47/44 (2017.01); A61K 39/39 (2006.01); C07C 229/08 (2006.01); A61K 31/713 (2006.01); C07D 319/06 (2006.01); C07D 317/28 (2006.01); C07D 203/10 (2006.01); C07C 229/30 (2006.01); C12N 15/113 (2010.01); A61K 39/00 (2006.01); C12N 15/11 (2006.01); A61K 9/127 (2006.01); A61K 47/10 (2017.01); A61K 47/18 (2017.01); A61K 47/20 (2006.01); A61K 47/28 (2006.01); C07C 237/16 (2006.01); C07C 251/38 (2006.01); C07C 251/78 (2006.01); C07C 271/12 (2006.01); C07C 271/20 (2006.01); C07C 323/25 (2006.01); A61K 31/7088 (2006.01); C07D 317/44 (2006.01); C07D 317/46 (2006.01); C07D 317/72 (2006.01); C07D 405/12 (2006.01); C07D 491/056 (2006.01); C07D 491/113 (2006.01)
CPC A61K 47/44 (2013.01) [A61K 9/1272 (2013.01); A61K 31/7088 (2013.01); A61K 31/713 (2013.01); A61K 39/00 (2013.01); A61K 39/39 (2013.01); A61K 47/10 (2013.01); A61K 47/18 (2013.01); A61K 47/20 (2013.01); A61K 47/28 (2013.01); C07C 229/08 (2013.01); C07C 229/30 (2013.01); C07C 237/16 (2013.01); C07C 251/38 (2013.01); C07C 251/78 (2013.01); C07C 271/12 (2013.01); C07C 271/20 (2013.01); C07C 323/25 (2013.01); C07D 203/10 (2013.01); C07D 317/28 (2013.01); C07D 317/44 (2013.01); C07D 317/46 (2013.01); C07D 317/72 (2013.01); C07D 319/06 (2013.01); C07D 405/12 (2013.01); C07D 491/056 (2013.01); C07D 491/113 (2013.01); C12N 15/111 (2013.01); C12N 15/113 (2013.01); A61K 2039/55555 (2013.01); A61K 2039/55561 (2013.01); C12N 2310/14 (2013.01); C12N 2310/3515 (2013.01); C12N 2320/32 (2013.01); Y02A 50/30 (2018.01)] 16 Claims
 
1. A lipid having the structure

OG Complex Work Unit Chemistry
E is C(O)O or OC(O);
R1 and R2 and Rx are each independently for each occurrence H, optionally substituted C1-C10 alkyl, or optionally substituted C10-C30 acyl, provided that at least one of R1, R2 and Rx is not H;
R3 is optionally substituted C2-C10 alkenyl, optionally substituted C2-C10 alkynyl, alkylheterocycle, alkylphosphate, alkylphosphorothioate, alkylphosphorodithioate, alkylphosphonate, alkylamine, hydroxyalkyl, ω-aminoalkyl, ω-(substituted)aminoalkyl, ω-phosphoalkyl, ω-thiophosphoalkyl heteroaryl, or heterocycle; and
n is 0, 1, 2, or 3.